Evidence map›Paper›PMID 38187389›Full record

ArticleFrontiers in immunology2023

B-cell-specific

Mary Melissa Roland, Tori E Peacock, Nia Hall, Ahmed Dawood Mohammed, Ryan Ball, Amy Jolly, Sergei Alexeev, Nicolas Dopkins, Mitzi Nagarkatti, Prakash Nagarkatti and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Mary Melissa RolandDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Tori E PeacockDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Nia HallDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Ahmed Dawood MohammedDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Ryan BallDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Amy JollyDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Sergei AlexeevDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Nicolas DopkinsDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Mitzi NagarkattiDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Prakash NagarkattiDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
Jason L KubinakDepartment of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, Columbia, SC, United States.
University of South Carolina · US

Funding

Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
B-cell-intrinsic MHCII Signaling is a Diversifying Force of Selection on IgA Repertoires and the Gut MicrobiotaR01AI155887 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KUBINAK, JASON L · 2021 to 2025
$2.1M
BD FACSymphony A5 Cell AnalyzerS10OD032271 · OD · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KUBINAK, JASON L, PRICE, ROBERT L · 2022 to 2022
$513k
Humoral immunodeficiency disrupts bile-acid-induced immune tolerance in the small intestineR56AI162986 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI KUBINAK, JASON L · 2022 to 2022
$247k
NIAID NIH HHS R01 AI155887NIAID NIH HHS R56 AI162986NIGMS NIH HHS P20 GM103641NIH HHS S10 OD032271
6 · The paper itself

Abstract

Background: The expression of major histocompatibility complex class II ( Methods: Here, we developed a novel Results: Results from our experiments indicate that SLO development and reconstitution of an anti-commensal TD IgA response can be induced in Conclusion: Our data also clearly establishes that

Indexed as

Immunoglobulin AMicrobiotaAnimalsAntilymphocyte SerumB-LymphocytesGenes, MHC Class IIHomeodomain ProteinsMiceRNA, Ribosomal, 16SAntilymphocyte SerumHomeodomain ProteinsImmunoglobulin ARNA, Ribosomal, 16Sadaptive immunityIgAMhcIImicrobial ecologymicrobiota

Identifiers

PMID38187389
PMCPMC10766766
OpenAlexW4390111190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.